ÌÇÐÄÆƽâ°æ

Novo Nordisk's sales distribution by therapeutic area from 2021 to 2025

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2026

Region

Worldwide

Survey time period

2021 to 2025

Supplementary notes

* Calculated based on provided sales figures. Sums may not add up to 100 percent due to rounding effects.

Citation formats

Novo Nordisk sales share by therapy area 2021-2025

Published by A. Minhas, Feb 13, 2026

In both 2021 and 2022, Danish drug manufacturer Novo Nordisk generated * of its total sales in the diabetes care segment. However, in 2025, the diabetes segment decreased 67percent, while the obesity segment increased its share from **** to ** percent. That was to a large extent due to the strong sales performance of the weight loss drug Wegovy.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Novo Nordisk "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Novo Nordisk

Global positioning

6

Key metrics

4

Segments

4

Competitors

5

Diabetes & weight loss - a growing market

5

Further Content: You might find this interesting as well

Topics

Novo NordiskGlobal pharmaceutical industryPharmaceutical industry in the U.S.DiabetesDiabetes in China
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.